Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 81Carcinoma, Non-Small-Cell Lung 76Neoplasms 71Ovarian Neoplasms 68Neoplasm Metastasis 30Fallopian Tube Neoplasms 30Carcinoma, Ovarian Epithelial 29Lung Neoplasms 26Unspecified Adult Solid Tumor, Protocol Specific 24Triple Negative Breast Neoplasms 20Endometrial Neoplasms 20Esophageal Neoplasms 18Stomach Neoplasms 16Colorectal Neoplasms 14Squamous Cell Carcinoma of Head and Neck 13Head and Neck Neoplasms 13Solid Tumors 12Small Cell Lung Carcinoma 10Melanoma 10Pancreatic Neoplasms 9Uterine Cervical Neoplasms 8Prostatic Neoplasms 8Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma 8Carcinoma, Renal Cell 8Carcinoma 8Brenner Tumor 8Urinary Bladder Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7

Interventions

entinostat 2Gemcitabine 2pembrolizumab 1napabucasin 1interferon gamma-1b 1VB6-845 fusion protein 1Taxes 1Paclitaxel 1Oncolytic Virotherapy 1Nivolumab 1Leucovorin 1Irinotecan 1Interferon-gamma 1Immunotherapy 1Fluorouracil 1Cobicistat 1Cell Count 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms, Glandular and Epithelial × Paclitaxel × Clear all
NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡